STOCK TITAN

TherapeuticsMD, Inc. - $TXMD STOCK NEWS

Welcome to our dedicated page for TherapeuticsMD news (Ticker: $TXMD), a resource for investors and traders seeking the latest updates and insights on TherapeuticsMD stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect TherapeuticsMD's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of TherapeuticsMD's position in the market.

Rhea-AI Summary
TherapeuticsMD, Inc. reported financial results for the full year ended December 31, 2023, with a net loss from continuing operations of $(7.7) million. The company generated gross license royalties of approximately $4.5 million under the Mayne License Agreement. Total operating expenses decreased by 85.4% to $9.8 million in 2023. TherapeuticsMD continues to evaluate strategic alternatives to maximize shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.31%
Tags
-
Rhea-AI Summary
TherapeuticsMD, Inc. (NASDAQ: TXMD) reported Q3 2023 financial results, emphasizing cost control to maximize royalty assets' value. Net loss from continuing operations decreased by 90.1% compared to Q3 2022. License and service revenues from continuing operations decreased, but gross royalties totaled $1.2 million and $3.3 million for the three- and nine-month periods ended September 30, 2023, respectively. The company announced an evaluation of strategic alternatives, including acquisition, merger, or sale of assets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.41%
Tags
-
Rhea-AI Summary
TherapeuticsMD, Inc. (TXMD) reported financial results for the second quarter ended June 30, 2023. The company's net loss from continuing operations decreased to $2.4 million compared to $14.9 million in the same period in 2022. License and service revenues from continuing operations increased to $0.4 million. Total operating expenses from continuing operations decreased to approximately $2.9 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.78%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.23%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.81%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.06%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.2%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.21%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.53%
Tags
none
TherapeuticsMD, Inc.

Nasdaq:TXMD

TXMD Rankings

TXMD Stock Data

22.60M
9.91M
3.78%
28.2%
0.39%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
BOCA RATON

About TXMD

therapeuticsmd, inc. is an innovative pharmaceutical company exclusively committed to advancing the health of women and championing awareness of their health care issues. we create products to address the unique changes and challenges women experience through every stage of their lives. with momentum fueled by the needs of our customers, we combine entrepreneurial spirit and clinical expertise to develop innovative solutions designed to go beyond what is presently available. this includes a variety of therapies in our pipeline, along with prescription prenatal vitamins under the vitamedmd® and bocagreenmd® brands. see our community guidelines: https://www.therapeuticsmd.com/social-media-community-guidelines